Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22433573 | 0.89 | — | — | |
| SCHEMBL22433304 | 0.87 | DRD2 (0.37) | — | |
| SCHEMBL20634274 | 0.87 | NLRP3 (0.45) | — | |
| SCHEMBL22433383 | 0.87 | — | — | |
| SCHEMBL22433439 | 0.85 | NLRP3 (0.51) | — | |
| SCHEMBL22433080 | 0.85 | MEN1 (0.46) | MEN1KMT2ATDP1 | |
| SCHEMBL20636166 | 0.85 | MEN1 (0.46) | MEN1KMT2ATDP1 | |
| SCHEMBL20636172 | 0.85 | MEN1 (0.46) | MEN1KMT2ATDP1 | |
| SCHEMBL20636156 | 0.84 | NLRP3 (0.50) | — | |
| SCHEMBL22433082 | 0.83 | NLRP3 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | MEN1 4099/4885KMT2A 2805/4885TDP1 1474/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | MEN1 4122/4885KMT2A 2774/4885TDP1 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.